《美股业绩》AbbVie季绩胜预期 料Botox全年销售升62%
抗体药修美乐(Humira)及肉毒杆菌素保妥适(Botox)生产商艾怕维(AbbVie)(ABBV.US)公布季度业绩。季度纯利35.53亿美元,按年升18%。每股季度摊薄纯利1.99美元,经调整後为2.95美元,高於市场预期的2.83美元。季度净收益130.1亿美元,按年升50.9%,高於市场预期的127.6亿美元。
保妥适季度销售按年升45%至4.47亿美元,受惠於新冠疫苗接种後美国需求反弹。公司预期保妥适全年销售19亿美元,按年升62%。公司亦上调全年经调整每股盈利预测,由介乎12.32至12.52美元上调至介乎12.37至12.57美元。
艾伯维股价上周五(30日)逆市靠稳升0.6%,报111.5美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.